Predicting Factors for Mortality in Congenital Heart Disease Patients After Shunt Procedure in Developing Country.

Cyanotic Congenital Heart Disease Clinical Trial

Official title:
Predicting Factors for Mortality in Patients After the Modified Blalock-Taussig Shunt Procedure in Developing Country: a Retrospective Study

Status Completed

Clinical Trial Summary

Blalock Taussig (BT) is a palliative procedure that preserves blood circulation to the lungs and alleviates cyanosis in patients with congenital heart diseases and reduced pulmonary blood flow. BT shunt remains a routinely performed procedure in developing countries before definitive surgery. However, evidence on predictors factors of mortality after this procedure is still scarce in Indonesia.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Cyanotic Congenital Heart Disease
Heart Defects, Congenital
Heart Diseases

Clinical Trial Details

NCT number	NCT05800691
Study type	Observational
Source	Universitas Sumatera Utara
Contact
Status	Completed
Phase
Start date	November 1, 2020
Completion date	January 31, 2021

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT02564796` - Erythropoietin to Prevent Unnecessary Transfusions In Patients With Cyanotic CHD - A Prospective Control Trial	Phase 2
Completed	`NCT01018472` - Probiotics in Infants With Cyanotic Congenital Heart Disease	N/A
Recruiting	`NCT04891081` - Plasma Metanephrines in Patients With Cyanotic and Acyanotic Congenital Heart Disease
Completed	`NCT02712606` - Accuracy of Pulse Oximeter With Hypoxemic Measurements
Completed	`NCT01426542` - Preventing Brain Injury in Infants With Congenital Heart Disease	Phase 1
Completed	`NCT03678909` - Cardiac Biomarkers in Patients With Single Ventricle Physiology
Completed	`NCT04125550` - Propofol vs Sevoflurane in Cyanotic Congenital Heart Disease	Phase 4